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PRESS RELEASE 
SUBJECT LINE: Okayama University Research: Innovative non-invasive ‘liquid biopsy’ 
method to capture circulating tumor cells from blood samples for genetic testing 
 
Source: Okayama University, Planning and Public Information Division 
For immediate release: 10 July 2014  
(Okayama, Japan, 10 July 2014) Okayama University medical researchers seek partners 
to commercialize their clinically proven non-invasive fluorescence virus-guided capture 
system of human colorectal circulating tumor cells (CTCs) from blood samples for 
genetic testing. This form of non-invasive companion diagnostics is important for 
personalized targeted cancer therapy.  
 
The research is led by Professor Toshiyoshi Fujiwara, Okayama University Graduate 
School of Medicine, Dentistry, and Pharmaceutical Sciences and was published in Gut 
May 2014 [1] 
 
The key factor in capturing extremely low quantities of live CTCs from millions of 
background blood leukocytes is targeting the high telomerase activity of malignant 
tumor cells with green fluorescent protein (GFP) expressing telomerase specific 
replication adenovirus (OBP-401, TelomeScan [2,3]).  
 
Notably, Professor Fujiwara and colleagues have previously reported on clinical tests on 
OBP-401 based GFP labelling to detect live CTCs in gasterointestinal and ovarian 
cancers.  
 
Here, Professor Fujiwara and his team show that their OBP-401 based CTC capture 
system enables the monitoring of genetic mutations in both epithelial and 
mesenchymal types of CTCs, thereby opening up the possibility of a new non-invasive 
companion diagnostic method for genetic testing and personalized medicine.  
 
“This ‘liquid biopsy’ via a simple blood test could be carried out in real time and 
enables optimized and timely decisions for therapeutic intervention,” state the 
researchers.  
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Background and relevance of this research  
 
In 1869 Thomas Ashworth first reported the presence of circulating tumor cells (CTCs) 
in patients with advanced cancer in his paper entitled: "A case of cancer in which cells 
similar to those in the tumors were seen in the blood after death". (Australian Medical 
Journal 14: 146–7, (1869)).  
 
However, it is challenging to detect CTCs because there are very small quantities of 
CTCs in the bloodstream. The so-called CellSearch system is widely used to detect CTCs, 
where antibodies are used to target the major epithelial cell surface marker known as 
the epithelial cell adhesion molecule (EpCAM).  
 
Importantly, recent research has shown the existence of heterogeneous CTCs that have 
both epithelial and mesenchymal characteristics. This discovery has led to demand for 
the development of CTC capture systems that are able to detect CTCs irrespective of 
the epithelial cell marker for cancer treatment with molecularly targeted drugs. 
 
Another important fact is that currently, targeted cancer treatment for individual 
patients is carried out by analysis of primary tumors. The difficulties with this approach 
are that the primary tumors contain very few cells that cause metastasis or 
reoccurrence, and samples for analysis are obtained by needle core biopsies or surgical 
removal of tumor tissue—which are invasive procedures and prohibit the extraction of 
tissue from locations inaccessible by surgery.  
 
So there is the need for non-invasive methods capable of detecting CTCs independent 
of the epithelial cell marker.  
 
Details and conclusions described in Gut [1]  
 
(1) The OBP-401-based CTC capture system developed by Okayama University can be 
used to genetic testing of CTCs with mesenchymal characteristics, including GISTs and 
osteosarcomas.  
(2) Combining OBP-401-based CTC capture system and genetic testing enabled the 
detection of KRAS and BRAF mutations in blood samples taken from patients with 
colorectal cancer. Notably, these mutations were determined to be identical to the 
ones seen in the primary tumours of the patients.   
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(3) This technology requires large scale testing.  
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[2] The manufacturer of OBP-401 (TelomeScan) is Oncolys BioPharma Inc:  
http://www.oncolys.com/en/pipeline/obp-1101.html 
 
[3] Patents owned by Oncolys BioPharma Inc: 
http://www.oncolys.com/en/company-information/patent.html 
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About Okayama University 
Okayama University is one of the largest 
comprehensive universities in Japan with 
roots going back to the Medical Training 
Place sponsored by the Lord of Okayama 
and established in 1870. Now with 1,300 
faculty and 14,000 students, the University 
offers courses in specialties ranging from 
medicine and pharmacy to humanities 
a n d  p h y s i c a l  s c i e n c e s .  O k a y a m a 
University is located in the heart of Japan 
approximately 3 hours west of Tokyo by 
Shinkansen. 
